These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 30998101)
1. Clinical value of molecular MRD monitoring by next-generation sequencing in patients with Shumilov E; Flach J; Joncourt R; Porret N; Wiedemann G; Novak U; Gfeller E; Jeker B; Amstutz U; Pabst T; Bacher U Leuk Lymphoma; 2019 Oct; 60(10):2588-2590. PubMed ID: 30998101 [No Abstract] [Full Text] [Related]
2. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia. Yang F; Anekpuritanang T; Press RD Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884 [TBL] [Abstract][Full Text] [Related]
3. Minimal/Measurable Residual Disease Monitoring in Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199 [TBL] [Abstract][Full Text] [Related]
4. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions. DiNardo C; Lachowiez C Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639 [TBL] [Abstract][Full Text] [Related]
5. IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring? Petrova L; Vrbacky F; Lanska M; Zavrelova A; Zak P; Hrochova K Clin Biochem; 2018 Nov; 61():34-39. PubMed ID: 30176240 [TBL] [Abstract][Full Text] [Related]
6. [Research Advances of IDH2 Gene Mutation in Acute Myeloid Leukemia]. Zhao YX; Shen XL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):632-6. PubMed ID: 27151043 [TBL] [Abstract][Full Text] [Related]
7. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081 [TBL] [Abstract][Full Text] [Related]
8. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321 [TBL] [Abstract][Full Text] [Related]
9. The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia. Bewersdorf JP; Shallis RM; Boddu PC; Wood B; Radich J; Halene S; Zeidan AM Blood Rev; 2020 Sep; 43():100650. PubMed ID: 31883804 [TBL] [Abstract][Full Text] [Related]
10. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations. Zheng WS; Hu YL; Guan LX; Peng B; Wang SY Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943 [TBL] [Abstract][Full Text] [Related]
11. Novel Tools for Diagnosis and Monitoring of AML. Guijarro F; Garrote M; Villamor N; Colomer D; Esteve J; López-Guerra M Curr Oncol; 2023 May; 30(6):5201-5213. PubMed ID: 37366878 [TBL] [Abstract][Full Text] [Related]
12. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia. Aitken MJL; Ravandi F; Patel KP; Short NJ J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626 [TBL] [Abstract][Full Text] [Related]
13. Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia. Murphy T; Zou J; Arruda A; Wang TT; Zhao Z; Zheng Y; Gupta V; Maze D; McNamara C; Minden MD; Schimmer A; Sibai H; Yee K; Capo-Chichi JM; Stockley T; Schuh A; Bratman SV; Chan SM Haematologica; 2024 Feb; 109(2):671-675. PubMed ID: 37345484 [No Abstract] [Full Text] [Related]
14. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia. Yu T; Chi J; Wang L Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615 [TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome. Shapiro RM; Kim DDH Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033 [TBL] [Abstract][Full Text] [Related]
16. Minimal Residual Disease assessment of IDH1/2 mutations in Acute Myeloid Leukemia by LNA-RQ-PCR. Abdelhamid E; Besbes S; Renneville A; Nibourel O; Helevaut N; Preudhomme C; Soua Z Tunis Med; 2016 Mar; 94(3):190-7. PubMed ID: 27575502 [TBL] [Abstract][Full Text] [Related]
17. Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions. Selim AG; Moore AS J Mol Diagn; 2018 Jul; 20(4):389-397. PubMed ID: 29689379 [TBL] [Abstract][Full Text] [Related]
18. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365 [TBL] [Abstract][Full Text] [Related]
19. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia. Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876 [TBL] [Abstract][Full Text] [Related]
20. Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene. Jeziskova I; Razga F; Toskova M; Dvorakova D; Timilsina S; Mayer J; Racil Z Leuk Lymphoma; 2013 Apr; 54(4):867-70. PubMed ID: 22950897 [No Abstract] [Full Text] [Related] [Next] [New Search]